Core Insights - Tarsus Pharmaceuticals focuses on unmet medical needs in eye care, particularly through first-in-class therapeutics and a specialized commercial infrastructure [1][2] Company Overview - Tarsus targets ophthalmologists and dermatologists, developing therapeutics for conditions like Demodex blepharitis and meibomian gland disease, with additional products in the pipeline for rosacea and Lyme disease [2] - The company generated $451.4 million in net product sales in 2025, more than doubling from the previous year, with fourth-quarter sales reaching $151.7 million and gross margins around 93% [8] Financial Performance - Despite remaining unprofitable, Tarsus narrowed its net loss to $66.4 million in 2025 and ended the year with over $417 million in cash and marketable securities, providing a runway for pipeline expansion [8] Insider Transactions - Dianne C. Whitfield, Chief Human Resources Officer, sold 12,274 shares, representing 25.95% of her direct holdings, in a transaction tied to tax withholding rather than a signal on company fundamentals [6][7][4] - The sale exceeded the median insider sale of 9,835 shares over the past year, but aligns with her recent pattern of reducing holdings [5] Market Context - The weighted average sale price of Tarsus shares was approximately $68.36, with a total return of 22.48% over the past year as of the transaction date [3]

Core Insights - The company is a few years into the launch of its product XDEMVY, indicating a relatively recent entry into the market [1] Company Overview - Tarsus is the company in focus, and there is a request for an overview of its operations and timeline regarding the approval and launch of XDEMVY [1]

Tarsus Pharmaceuticals FY Conference Summary Company Overview - **Company Name**: Tarsus Pharmaceuticals - **Ticker**: NasdaqGS:TARS - **Headquarters**: Irvine, California - **Product**: XDEMVY for the treatment of Demodex blepharitis, a prevalent eye disease caused by Demodex mites [4][5] Financial Performance - **2023 Approval**: XDEMVY was approved in August 2023 [4] - **2023 Revenue**: Approximately $450 million, treating about 500,000 patients [4] - **Market Potential**: 25 million patients affected by Demodex blepharitis; 9 million are immediately addressable [5][24] - **2026 Revenue Guidance**: Expected top-line revenue between $690 million and $700 million [5] - **Long-term Peak Sales Potential**: Estimated at around $2 billion [5][35] Market Dynamics - **Market Education**: Tarsus has created a new category for Demodex blepharitis, previously unfamiliar to many doctors [10] - **Payer Coverage**: Achieved 90% prior payer coverage, with a gross to net discount of about 44% [12][13] - **Sales Force Expansion**: Started with a 100-person sales force, increased by 50% within the first year, and added 15-20 key account leaders recently [15][16] Prescriber Engagement - **Current Prescribers**: Over 20,000 prescribers, with 15,000 responsible for 85% of prescriptions [17] - **Utilization Growth**: 40% of prescribers write prescriptions weekly; daily prescribers have increased by 20% since the last quarter [18][19] Direct-to-Consumer (DTC) Campaign - **Campaign Launch**: Initiated last year, combining targeted streaming and network TV ads [21][22] - **Impact**: Increased awareness, with one in four patients now asking for XDEMVY by name [25] Seasonal Trends and Guidance - **Q1 Trends**: Typically sees a drop in prescriptions due to deductible resets; expected recovery in Q2 [28][31] - **Growth Expectations**: Anticipated 50%+ growth for 2026, with a stable payer base and historical data to support guidance [26][27] Pipeline Development - **Ocular Rosacea Program**: Phase II study initiated for a sterile gel formulation targeting ocular rosacea, with results expected in the first half of next year [38][39] - **Lyme Disease Prevention**: Phase II study for an oral tablet targeting Lyme disease, with data expected in the first half of next year [40] Financial Position - **Balance Sheet Strength**: Over $400 million in cash and equivalents, minimal debt, and nearing profitability [41] Market Perception and Stock Response - **Investor Sentiment**: Skepticism regarding the disease's awareness and the stock's response to script trends; viewed as a buying opportunity given strong guidance [43][44] Conclusion - Tarsus Pharmaceuticals is positioned for significant growth with a strong product offering, expanding market presence, and a robust pipeline, while navigating investor perceptions and market dynamics effectively.

Core Insights - Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is recognized as one of the 10 Fastest Growing NASDAQ Stocks to Buy [1] - Analysts have raised price targets for Tarsus following strong quarterly results and positive sales guidance for its product XDEMVY [2][3] Financial Performance - Tarsus reported Q4 EPS of (20 cents), which was below consensus estimates of (13 cents) [3] - Q4 revenue reached $151.67 million, exceeding the consensus estimate of $144.56 million [3] - The company provided FY26 net product sales guidance of $670 million to $700 million for XDEMVY, indicating a year-over-year increase of $230 million [2] Market Position and Growth Potential - The sales guidance for 2026 positions XDEMVY to potentially achieve over $2 billion in peak U.S. sales [2] - Tarsus has only penetrated a small portion of the estimated 25 million patient Demodex blepharitis market, suggesting significant room for growth [3] - The CEO highlighted that XDEMVY has initiated a fundamental shift in eye care, establishing a growing franchise within two years of its launch [3] Analyst Ratings - Oppenheimer raised its price target on Tarsus to $105 from $95 and maintained an Outperform rating [2] - Guggenheim increased its price target to $90 from $87 and reiterated a Buy rating, citing strong 2025 results [3]

Tarsus Pharmaceuticals FY Conference Summary Company Overview - Tarsus Pharmaceuticals is a Southern California-based company focused on pioneering new categories in eye care, particularly with its flagship product XDEMVY, which targets Demodex blepharitis, a condition affecting approximately 25 million Americans [2][3]. Financial Performance - Tarsus reported over $450 million in revenue in the second year of XDEMVY's launch, positioning it on a path to become a blockbuster with peak sales projected to exceed $2 billion [3][6]. - The company anticipates achieving this peak sales figure with less than 10% market penetration of the estimated 25 million patients suffering from demodicosis [12]. Product Pipeline - Tarsus is developing additional products, including: - **TP-04**: A candidate for treating Ocular Rosacea, currently in Phase 2 trials, addressing a significant unmet need with no approved therapies available [4][56]. - **TP-05**: A prophylactic treatment for Lyme disease, showing promising Phase IIa data with a 95% tick kill rate within 24 hours [5][66]. Market Dynamics and Growth Strategy - The company has successfully educated over 20,000 doctors about XDEMVY, with a strategy focused on increasing prescribing frequency from monthly to daily [25][27]. - Tarsus has invested approximately $80 million in direct-to-consumer advertising, significantly raising awareness of Demodex blepharitis from 0% to 25% among patients [32][33]. - The company has achieved 90% payer coverage, ensuring broad access to XDEMVY for patients [37]. Sales Guidance and Market Expectations - Tarsus provided sales guidance for the upcoming year, projecting revenue between $670 million and $700 million, with expectations of 50% growth [40][48]. - The company anticipates a flat to slightly down revenue in Q1 due to seasonal factors affecting patient visits [49][51]. Clinical Insights and Physician Feedback - Feedback from physicians indicates a strong belief in XDEMVY's efficacy, with many doctors surprised by the low number of treated patients compared to the potential market size [9][10]. - The company is focused on demonstrating proof of concept for TP-04 and TP-05, with expected data readouts in the first half of 2027 [59][68]. Strategic Expansion - Tarsus is exploring opportunities to expand its pipeline, focusing on category-creating products in the anterior segment of the eye, with plans to eventually move into retinal diseases [74][76]. - The company aims to leverage its strong sales force to introduce new products effectively and maintain growth momentum [72][79]. Conclusion - Tarsus Pharmaceuticals is positioned for significant growth with its innovative approach to eye care, a strong product pipeline, and effective market strategies. The company is focused on addressing unmet medical needs and expanding its market presence through education and awareness initiatives.

Core Insights - The company achieved $450 million in full-year net sales for 2025, positioning XDEMVY as a leading therapeutic in the eye care sector [1] - Profitability was attained at the product line level for XDEMVY, allowing for financial flexibility to reinvest in high-return growth opportunities [1] - The addressable market was expanded from an initial focus on 9 million patients to encompass the full 25 million Americans suffering from Demodex blepharitis, as routine screening becomes more common [1] Commercial Success Factors - The commercial success is attributed to a 'repeatable playbook' that identifies diseases with clear root causes and utilizes established development and commercial frameworks [1] - A notable shift in practice behavior was observed, with eye care professionals now screening for the disease among a broader range of patient types, including those with glaucoma and styes [1] - Direct-to-consumer awareness of the treatment reached 25% among surveyed patients, significantly increasing the number of patients proactively requesting the treatment by name [1]

Financial Data and Key Metrics Changes - In 2025, Tarsus Pharmaceuticals achieved over $450 million in full-year net sales, with Q4 net product sales reaching $151.7 million at a gross net discount of 44% [4][22] - The company ended the year with approximately $418 million in cash, cash equivalents, and marketable securities, providing financial flexibility for growth [22] - For 2026, Tarsus expects net product sales in the range of $670 million to $700 million, representing an annual growth of over $230 million and 50% at the midpoint of guidance [23] Business Line Data and Key Metrics Changes - XDEMVY, the company's primary product, is now profitable and growing, with significant market penetration potential among the estimated 25 million Americans living with Demodex blepharitis [8][9] - The company plans to add approximately 15-20 key account leaders to enhance sales force effectiveness in 2026 [10] Market Data and Key Metrics Changes - Tarsus has over 90% coverage across commercial Medicare and Medicaid, which is expanding the funnel of diagnosed and treated patients [10] - The company has seen a shift in eye care professionals' (ECPs) practice behavior, with many now screening for Demodex blepharitis in patients with other eye conditions [9][10] Company Strategy and Development Direction - Tarsus aims to build on the success of XDEMVY by applying its proven development and commercial playbook to new programs, including TP-04 for ocular rosacea and TP-05 for Lyme disease prevention [5][6] - The company plans to expand its pipeline by targeting one to two new programs per year, allowing for focused growth and responsible capital allocation [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of XDEMVY, citing strong fundamentals and a growing base of prescribers [8][9] - The company anticipates typical first-quarter seasonality to impact growth, with expectations for a strong second quarter and robust growth in the fourth quarter of 2026 [23][24] Other Important Information - Tarsus is actively pursuing global regulatory approvals for TP-03, with potential approvals expected in Europe and Japan in 2027 [20][21] - The company has welcomed David Pyott to its board, enhancing its leadership in the biopharmaceutical industry [6][7] Q&A Session Summary Question: Can you provide more detail on expectations beyond Q1 for the $670 million-$700 million guidance? - Management indicated that Q1 is expected to be flat to slightly down due to typical seasonal dynamics, with a strong growth anticipated in Q2 [32][33] Question: What is driving the increased peak sales target to over $2 billion? - The increase is attributed to a growing prescriber base and deeper utilization among top-tier prescribers, along with continued flawless execution in commercial efforts [42][43] Question: Can you elaborate on the DTC campaign and its ROI? - The DTC campaign has performed exceptionally well, achieving positive ROI earlier than expected, and management plans to maintain the $80 million spend while also investing in the sales force [46][48] Question: What are the expected costs for the pivotal studies for ocular rosacea and Lyme disease? - The ocular rosacea study is expected to cost between $7 million and $10 million, while the Lyme disease study is projected to cost between $25 million and $30 million [75][76] Question: What are the current prescribing trends between ophthalmologists and optometrists? - The prescribing dynamics show strong growth in both segments, with approximately 40% of the core target prescribing weekly [79]

Financial Data and Key Metrics Changes - In 2025, Tarsus Pharmaceuticals achieved over $450 million in full-year net sales, with Q4 net product sales reaching $151.7 million at a gross-to-net discount of 44% [4][22] - Total operating expenses for 2025 were $522.3 million, primarily due to commercial investments for the XDEMVY launch [22] - The company ended 2025 with approximately $418 million in cash, cash equivalents, and marketable securities, providing financial flexibility for growth [22] Business Line Data and Key Metrics Changes - XDEMVY, the company's primary product, is now profitable and growing, with expectations of reaching blockbuster status with sales potential exceeding $2 billion [5][8] - The company has helped over 500,000 patients with Demodex blepharitis since the product's launch, indicating significant market penetration [4] - The company plans to add approximately 15-20 key account leaders in 2026 to enhance sales force effectiveness [10] Market Data and Key Metrics Changes - The U.S. market for Demodex blepharitis is estimated to have 25 million affected individuals, with significant growth potential as awareness and treatment options expand [8][9] - The company has achieved over 90% coverage across commercial Medicare and Medicaid, facilitating patient access [10] - Awareness of Demodex blepharitis and XDEMVY has increased from 2% to 25% among surveyed patients, reflecting successful marketing efforts [12] Company Strategy and Development Direction - Tarsus aims to build on the success of XDEMVY by identifying diseases with clear root causes and unmet needs, applying a proven development and commercial playbook [5][6] - The company plans to expand its pipeline with one to two new programs per year, focusing on ocular rosacea (TP-04) and Lyme disease prevention (TP-05) [6][18] - Tarsus is committed to becoming a leader in eye care by creating and leading new categories in the industry [7][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of XDEMVY, anticipating strong net product sales guidance for 2026 in the range of $670 million to $700 million [23] - The company expects typical first-quarter seasonality to impact growth, with a projected flat to slightly down revenue for Q1 2026 [24] - Management highlighted the importance of continued investment in direct-to-consumer campaigns and sales force to drive growth [11][49] Other Important Information - The company is advancing its clinical programs TP-04 and TP-05, with expected costs of $7 million-$10 million and $25 million-$30 million respectively for their trials [26][75] - Tarsus is also making progress with TP-03 for potential regulatory approval in Europe and Japan, with expectations for approval in China later this year [20] Q&A Session Summary Question: Can you provide more detail on expectations beyond Q1 for the $670 million-$700 million guidance? - Management indicated that Q1 is expected to be flat to slightly down due to typical seasonal dynamics, with a strong growth anticipated in Q2 [32][34] Question: What is driving the increased conviction for the $2 billion peak sales target? - Management noted that the growth is driven by a strong prescriber base and continued flawless execution across commercial efforts [42] Question: Can you elaborate on the DTC campaign and its ROI? - The DTC campaign has performed exceptionally well, achieving positive ROI earlier than expected, and management plans to maintain the $80 million spend level [46][48] Question: What are the expected costs for the pivotal studies for ocular rosacea and Lyme disease? - The ocular rosacea study is expected to cost between $7 million-$10 million, while the Lyme disease study is projected to cost $25 million-$30 million [75] Question: Can you discuss the prescribing trends between ophthalmologists and optometrists? - The prescribing dynamics show strong growth in both segments, with approximately two-thirds of prescriptions coming from optometrists [78]

Financial Data and Key Metrics Changes - In 2025, Tarsus Pharmaceuticals achieved over $450 million in full-year net sales, with Q4 net product sales at $151.7 million and a gross-to-net discount of 44% [3][20] - Total operating expenses for 2025 were $522.3 million, primarily due to commercial investments for the XDEMVY launch [20] - The company ended 2025 with approximately $418 million in cash, cash equivalents, and marketable securities, providing financial flexibility for growth [20] Business Line Data and Key Metrics Changes - XDEMVY, the FDA-approved therapeutic for Demodex blepharitis, has helped over 500,000 patients since its launch and is expected to reach blockbuster status with sales potential exceeding $2 billion [3][4] - The company plans to expand its pipeline with two clinical-stage programs: TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, targeting one to two new programs per year [4][5] Market Data and Key Metrics Changes - The U.S. market for Demodex blepharitis is estimated to have 25 million affected individuals, with significant growth potential as awareness and treatment options expand [7][8] - Tarsus has achieved over 90% coverage across commercial Medicare and Medicaid, enhancing patient access [9] Company Strategy and Development Direction - Tarsus aims to create and lead new categories in eye care by identifying diseases with clear root causes and unmet needs, applying the successful development and commercial playbook established with XDEMVY [4][5] - The company is focused on disciplined growth, leveraging existing infrastructure while responsibly allocating capital to extend its long-term growth trajectory [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of XDEMVY, citing strong fundamentals and a growing base of prescribers [7][34] - The company anticipates strong net product sales guidance for 2026 in the range of $670 million to $700 million, representing over 50% growth at the midpoint [21][22] Other Important Information - Tarsus is preparing for the Phase 2 trial of TP-04, expected to cost between $7 million and $10 million, and the Phase 2 trial of TP-05, estimated at $25 million to $30 million [25][72] - The company is also making progress with TP-03 for potential regulatory approval in Europe and Japan, with expectations for approval in China later this year [19] Q&A Session Summary Question: Can you provide more detail on expectations beyond Q1 for the $370 million-$400 million guidance? - Management indicated that Q1 is expected to be flat to slightly down due to typical seasonal dynamics, with a strong growth anticipated in Q2 [31][32] Question: What is driving the increased conviction for the $2 billion peak sales target? - The increase is attributed to the broadening prescriber base and deeper engagement with top-tier prescribers, alongside continued flawless execution in commercial efforts [40][41] Question: Can you elaborate on the DTC campaign and its ROI? - The DTC campaign has performed exceptionally well, achieving positive ROI earlier than expected, and management plans to maintain the $80 million spend while also investing in the sales force [45][46] Question: What are the expected costs for the ocular rosacea and Lyme disease studies? - The ocular rosacea study is expected to cost between $7 million and $10 million, while the Lyme disease study is projected to cost $25 million to $30 million [72]

Building the Future of Eye Care Q4 & Full Year 2025 Financial Results February 2026 Vivian, an XDEMVY patient. World-Class Leadership Team With Proven Track Record of Success 2 | © Tarsus Pharmaceuticals | For Investor Purposes Only Bobby Azamian, MD, PhD CEO & Chairman Aziz Mottiwala Chief Commercial Officer Sesha Neervannan, PhD Chief Operating Officer Jeff Farrow Chief Financial & Strategy Officer Forward-looking Statements This presentation contains forward-looking statements that involve risks and unce ...